retatrutide clinical trial information Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide: What It Is &

For researchers focused primarily on metabolic markers, the 4mg to 8mg range appears to provide strong metabolic benefit with a favorable side effect profile

The Phase 2 clinical trial, published in the New England Journal of Medicine, demonstrated remarkable outcomes

Benefits Timeline Week 1-2: Food noise reduction, quieting of cravings begins Month 1: 2-4 pound loss typical, nausea under 10% for microdosers Month 3: 5-8% total body weight loss sustained Microdosing can support natural satiety and mindful eating, making it easier to build sustainable healthy habits rather than relying solely on the medication

Phase 3 means larger groups, longer timeframes, and more safety data

Make in India India is home to some of the worlds largest generic drug manufacturing companies